Candid Therapeutics

Private

Candid Therapeutics is a clinical-stage biotechnology company developing novel T-cell engager antibodies to treat autoimmune and inflammatory diseases. The company's platform redirects T-cells to selectively eliminate autoreactive B-cells, with clinical programs spanning five autoimmune indications. Founded by Ken Song after his $4.1B sale of RayzeBio to Bristol Myers Squibb.

Founders Ken Song
CEO Ken Song

Company

Founded
2024
Headquarters
San Diego, California, United States
Employees
11-50

Financials

Total Funding
$875M
Revenue (ARR)
pre-revenue
Sectors
Healthtech Biotech
www.candidrx.com Blog

Funding History

2 rounds
Undisclosed Mar 2, 2026
$505M
Venrock Healthcare Capital Partners RA Capital Management Janus Henderson T. Rowe Price venBio Partners Viking Global Investors Cormorant Asset Management Foresite Capital TCGX Vivo Capital
Series A Sep 9, 2024
$370M
Venrock Healthcare Capital Partners (Lead) Fairmount (Lead) TCGX (Lead) venBio Partners (Lead) Foresite Capital Third Rock Ventures Fidelity Management & Research Samsara BioCapital Qiming Venture Partners USA OrbiMed Boxer Capital Redmile Group Vida Ventures Franklin Templeton

Funding data is compiled from multiple independent sources including company announcements, press coverage, and regulatory filings. While we strive for accuracy, amounts and dates may reflect reported figures at time of announcement.